
EVAX Stock Forecast & Price Target
EVAX Analyst Ratings
Bulls say
Evaxion AS has shown positive momentum through its deepening partnership with Merck, which recently increased its stake in the company, signaling confidence in Evaxion's AI models and their commercial viability. With the removal of financial overhang from previous quarters, Evaxion is strategically positioned to advance its pipeline, targeting key milestones in 2025 that include pivotal efficacy data and new vaccine candidate announcements. Additionally, the company's successful capital raise of $7.9 million, alongside the compelling advantages of its AI-Immunology platform, further enhances its prospects for innovation and growth in both oncology and infectious diseases.
Bears say
The analysis indicates that Evaxion AS's approach using the AI-Immunology platform may lack significant differentiation in addressing tumor mutation burden (TMB)-low tumors, a segment where existing therapies have demonstrated limited success. This raises concerns about the company's ability to effectively compete in a crowded oncology market, potentially leading to decreased investor confidence. Furthermore, uncertainty regarding the commercial viability of their pipeline products could negatively impact future revenue streams and overall financial stability.
This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.
EVAX Analyst Forecast & Price Prediction
Start investing in EVAX
Order type
Buy in
Order amount
Est. shares
0 shares